Worldcrunch on MSN5d
Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’s
The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
Medscape5d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
News Medical on MSN1d
Finger prick on track to become Alzheimer's test
A quick finger prick and a few drops of blood on a card that can be sent in regular mail—This approach could soon make ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Hosted on MSN1d
The fight against Alzheimer’s disease: How effective and safe is lecanemab?
In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing authorization for the anti-Alzheimer's drug lecanemab. This follows an earlier ...
EurekAlert!1h
University Hospitals only health system in northeast Ohio offering FDA-approved KISUNLA™ for treatment of Alzheimer’s disease
University Hospitals Brain Health & Memory Center is now treating patients with KISUNLA™ (donanemab), a Food and Drug Administration-approved medication for the treatment of Alzheimer’s disease. UH is ...
Alzheimer's Research UK2d
“Crucial steps towards a cure” – my four take-homes from the Clinical Trials on Alzheimer’s Disease (CTAD) conference
Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...
Alzheimer’s patient, 90, says skiing and other activities keep him mentally sharp
Six years after his Alzheimer’s diagnosis, 90-year-old Zelik Bocknek (Zel) refuses to slow down — and he believes his active ...
DPA International on MSN5d
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...
GlobalData on MSN2d
How decentralisation can fill the gaps in Alzheimer’s research
Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
The Florida Times-Union8d
Alzheimer's is life-changing for 'everyone around them'; Jacksonville walkers show support
The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...